流式细胞术分析DNA倍型在肝细胞癌诊治中的应用

Application in diagnosis and treatment of hepatocellular cancer by analysing nuclear DNA ploidy by FCM.

目的 探讨肝细胞癌的DNA倍型分析在评估肝细胞癌转移、复发的风险中的临床应用价值。方法 采用流式细胞术(FCM)对25例肝细胞癌组织进行DNA倍型分析并与病理检查结果进行比较。结果 17例异倍体肝细胞癌中12例有癌栓和/或浸润,2例肝内转移;2例DNA二倍体、S期细胞比值(SPF)>19.6％的肝细胞癌组织病理检查1例有癌栓,另1例有包膜浸润;转移浸润率达84.2％(16/19)。6例DNA二倍体、SPF<19.6％的肝细胞癌组织均未发现癌栓和转移,仅2例有包膜浸润,浸润率为33.3％(2/6)。两者差异具有显著性意义(X2=5.855,P<0.05)。结论 DNA倍型分析可用于评估肝细胞癌转移、复发的风险,为临床制定有效的治疗方案,提供实验依据。

Objective To study clinical value of analysing nuclear DNA ploidy of hepatocellular cancer cell in assessment of metastasis and recurrence. Methods Analyse nuclear DNA ploidy of tissues from 25 patients with hepatocelluar cancer by FCM,then compare with pathological examination. Results Among the 17 cases aneuploidy liver cancers, 12 have carcinomatous emboli and&or infiltrations,2 have metastases; In two diploidy and S-phase faction(SPF) exceeding 19.6% cancers,one has carcinomatous embolus, the other has metastasis. The rate of metastasis and infiltration is 84.2% (16/19). In 6 diploidy and SPF normal cancers, only 2 have infiltrations. The rate of and infiltration is 33. 3% (2/6). Difference between them is significant(X2 = 5.855, P< 0.05). Conclusion Analysing nuclear DNA ploidy can give laboratory reference for clinial to assess recurrences or metastases of hepatocellular cancer and lay down effective treatment plan to prolong life -span of patients.